Document Detail


An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer.
MedLine Citation:
PMID:  17306348     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We previously demonstrated that that the Ras/ER/MDM2 pathway was critical for NIH3T3 cell transformation. In this study, we examined the effect of blocking this pathway on cell growth in gynecologic cancer cells. METHODS: (1) The levels of MDM2, ER, p53 and p21 in endometrial or ovarian cancer cell lines were investigated and compared with that in normal cells by Western blots. (2) The effects of MEK-inhibitor and/or anti-estrogen, and siRNA of MDM2 on cell growth, tumorigenicity in nude mice were examined. RESULTS: The MDM2 level was enhanced in cancer cells compared with normal cells. Treatment with MEK inhibitor(U0126) resulted in a reduced MDM2 level, enhanced p53 and p21 levels and inhibited cell growth by the induction of premature senescence. The effect of MEK inhibitor on cell growth was affected by ER levels and functions. Treatment with low-dose MEK inhibitor in combination with anti-estrogen (ICI182,780) had a more inhibitory effect on cell growth compared to treatment with MEK inhibitor or anti-estrogen alone in cancer cells. Down-regulation of the MDM2 level by siRNA resulted in the inhibition of growth in cancer cells. CONCLUSION: The blockage of the MAPK/ER/MDM2 pathway suppress cell proliferation and it is supposed as a new molecular target therapy in estrogen-dependent gynecologic cancers, such as endometrial or ovarian cancer.
Authors:
Shin Suga; Kiyoko Kato; Tatsuhiro Ohgami; Asako Yamayoshi; Sawako Adachi; Kazuo Asanoma; Shinichiro Yamaguchi; Takahiro Arima; Katsuyuki Kinoshita; Norio Wake
Related Documents :
12214268 - Role for the double-stranded rna activated protein kinase pkr in e2f-1-induced apoptosis.
8208528 - Effect of uv-irradiation on cell cycle, viability and the expression of p53, gadd153 an...
11807028 - Mutations in drosophila myb lead to centrosome amplification and genomic instability.
3801968 - Altered regulation of c-myc expression in adenovirus-transformed cells.
2972328 - Decreased ca pump atpase activity associated with increased density in human red blood ...
22053058 - Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-02-15
Journal Detail:
Title:  Gynecologic oncology     Volume:  105     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-23     Completed Date:  2007-05-31     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  341-50     Citation Subset:  IM    
Affiliation:
Department of Molecular Genetics, Division of Molecular and Cell Therapeutics, Medical Institute of Bioregulation, Kyushu University, Maidadhi 3-1-1, Higashi-ku, Fukuoka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Growth Processes / drug effects,  physiology
Cell Line, Tumor
Down-Regulation
Endometrial Neoplasms / drug therapy,  metabolism*,  pathology,  therapy*
Enzyme Inhibitors / pharmacology
Estradiol / analogs & derivatives,  pharmacology
Estrogen Receptor Modulators / pharmacology
Estrogen Receptor alpha / antagonists & inhibitors*,  metabolism
Female
Humans
MAP Kinase Kinase Kinases / antagonists & inhibitors*,  metabolism
MAP Kinase Signaling System
Ovarian Neoplasms / drug therapy,  metabolism*,  pathology,  therapy*
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*,  biosynthesis,  genetics,  metabolism
Proto-Oncogene Proteins p21(ras) / metabolism
RNA, Small Interfering / genetics
Tumor Suppressor Protein p53 / metabolism
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Estrogen Receptor Modulators; 0/Estrogen Receptor alpha; 0/RNA, Small Interfering; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 129453-61-8/fulvestrant; 50-28-2/Estradiol; EC 2.7.11.25/MAP Kinase Kinase Kinases; EC 3.6.5.2/Proto-Oncogene Proteins p21(ras); EC 6.3.2.19/MDM2 protein, human; EC 6.3.2.19/Proto-Oncogene Proteins c-mdm2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlates of sexual function following vulvar excision.
Next Document:  Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large si...